TLX

Telix Pharmaceuticals

Pharmaceuticals, Biotechnology & Life Sciences

Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for cancer treatment. The company focuses on precision oncology, utilizing targeted radiation to treat urologic, neurologic, and musculoskeletal cancers. Telix's unique value lies in its ability to deliver focused radiation doses with precision targeting, minimi...

Radiopharmaceuticals

Cancer Treatment

Precision Medicine

Theranostics

Shorted

short percentage12.30%

reported shorts41.7M

shares on issue338.777M

About

website

telixpharma.com

industry

Pharmaceuticals, Biotechnology & Life Sciences

address

55 Flemington Road, NORTH MELBOURNE, VIC, AUSTRALIA, 3051

Connect

More Pharmaceuticals, Biotechnology & Life Sciences Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

Radiopharmaceuticals

Cancer Treatment

Precision Medicine

Theranostics

Biotechnology

Company Overview

AI-generated company summary

Company History

Telix Pharmaceuticals was founded with the mission to advance precision care in cancer treatment. Over the years, the company has developed a robust pipeline of diagnostic and therapeutic radiopharmaceuticals. A significant milestone was the approval of its lead imaging agent, Illuccix®, by the FDA and TGA. Telix continues to expand its global presence with multiple clinical trials and regulatory approvals.

Competitive Advantages

Telix Pharmaceuticals has a strong global supply and distribution network, enabling efficient delivery of its products. The company's focus on precision targeting in radiopharmaceuticals allows for effective cancer treatment with minimal off-target effects. Additionally, Telix's extensive late-stage research portfolio positions it as a leader in the theranostics field.

Risk Factors

•Regulatory approval challenges
•High R&D costs
•Market competition

Recent Developments

Last 6 months

Telix has received global regulatory approvals for its prostate cancer imaging agent and is conducting over 18 clinical trials worldwide. The company continues to expand its research portfolio and commercial operations.

Key People

Leadership team at Telix Pharmaceuticals

CEO

CFO

Financial Reports

11 reports available

Telix H1 2025 Appendix 4D and Interim Report

Half Year ResultsAug 21, 2025via asx_announcements

2024 Full Year Results Presentation

Full Year ResultsFeb 20, 2025via asx_announcements

2024 Full Year Results Announcement

Full Year ResultsFeb 20, 2025via asx_announcements

Appendix 4E and 2024 Annual Report

Annual ResultsFeb 20, 2025via asx_announcements

Telix 2024 Full Year Results and Investor Webcast/Call

Full Year ResultsFeb 11, 2025via asx_announcements

Telix 1H 2024 Appendix 4D and Interim Report

Half Year ResultsAug 22, 2024via asx_announcements

Telix 2024 Half-Year Results Investor Webcast Notification

Half Year ResultsAug 13, 2024via asx_announcements

2023 Full Year Results Presentation

Full Year ResultsFeb 22, 2024via asx_announcements

2023 Full Year Results Release

Full Year ResultsFeb 22, 2024via asx_announcements

Appendix 4E and 2023 Annual Report

Annual ResultsFeb 22, 2024via asx_announcements

Showing 10 of 11 reports